Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
- 29 December 2009
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (52) , 22199-22204
Abstract
The unique glycolytic metabolism of most solid tumors, known as the Warburg effect, is associated with resistance to apoptosis that enables cancer cells to survive. Dichloroacetate (DCA) is an anticancer agent that can reverse the Warburg effect by inhibiting a key enzyme in cancer cells, pyruvate dehydrogenase kinase (PDK), that is required for the process. DCA is currently not approved for cancer treatment in the USA. Here, we present the synthesis, characterization, and anticancer properties ofc,t,c-[Pt(NH3)2(O2CHCl2)2Cl2], mitaplatin, in which two DCA units are appended to the axial positions of a six-coordinate Pt(IV) center. The negative intracellular redox potential reduces the platinum to release cisplatin, a Pt(II) compound, and two equivalents of DCA. By a unique mechanism, mitaplatin thereby attacks both nuclear DNA with cisplatin and mitochondria with DCA selectively in cancer cells. The cytotoxicity of mitaplatin in a variety of cancer cell lines equals or exceeds that of all known Pt(IV) compounds and is comparable to that of cisplatin. Mitaplatin alters the mitochondrial membrane potential gradient (Δψm) of cancer cells, promoting apoptosis by releasing cytochromecand translocating apoptosis inducing factor from mitochondria to the nucleus. Cisplatin formed upon cellular reduction of mitaplatin enters the nucleus and targets DNA to form 1,2-intrastrand d(GpG) cross-links characteristic of its own potency as an anticancer drug. These properties of mitaplatin are manifest in its ability to selectively kill cancer cells cocultured with normal fibroblasts and to partially overcome cisplatin resistance.Keywords
This publication has 41 references indexed in Scilit:
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- Targeted Single-Wall Carbon Nanotube-Mediated Pt(IV) Prodrug Delivery Using Folate as a Homing DeviceJournal of the American Chemical Society, 2008
- Dichloroacetate induces apoptosis in endometrial cancer cellsGynecologic Oncology, 2008
- Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor VasculatureBioconjugate Chemistry, 2007
- Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapyProceedings of the National Academy of Sciences, 2007
- Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nucleiNucleic Acids Research, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- The Hallmarks of CancerCell, 2000
- On the Origin of Cancer CellsScience, 1956